Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
View Patent ↗The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
1. A method of treatment of an angiogenesis-associated ocular disease comprising applying one or more doses of a chimeric or humanized anti-α5β1 integrin antibody to an injured eye tissue, wherein the anti-α5β1 integrin antibody comprises all of the complementary determining regions (CDRs) from SEQ ID NO: 25 and SEQ ID NO:26; and wherein the source of the constant region is a human IgG4.
2. The method of claim 1 , wherein the anti-α5β1 integrin antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 25 and a light chain consisting of the amino acid sequence of SEQ ID NO: 26.
3. The method of claim 1 , wherein the anti-α5β1 integrin antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 28 and a light chain consisting of the amino acid sequence of SEQ ID NO: 26.
4. The method of claim 1 , wherein the anti-α5β1 integrin antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 31 and a light chain consisting of the amino acid sequence of SEQ ID NO: 32.